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According to UNAIDS (the Joint United Nations 
Programme on HIV/AIDS), 33.3 million people 
worldwide are infected with HIV.  Of these, 10 million 
require treatment with anti-retroviral therapy (ART).1 
Currently, it is estimated that for every 100 people 
who receive treatment, there are 250 more people 
who become infected daily. This past October, the 
Global Fund to Fight AIDS, Tuberculosis and Malaria, 
an organization that provides treatment to roughly 
half of the world’s poor population, failed to meet its 
minimum fundraising target of $13 million, which 
is the minimum necessary to continue distributing 
anti-retroviral drugs to patients that have already 
started treatment.2 This failure only serves to force 
us to recognize the reality that some HIV-positive 
individuals will be fortunate enough to be treated 
with life-extending medications and some will not. 
Uganda provides a good example of the controversy 
surrounding global HIV/AIDS care and ART in 
resource-poor settings. During the 1990s, Uganda was 
viewed as a model for HIV/AIDS research, prevention, 
and public health education, and was one of the first 
countries in Africa to see a dramatic decrease in 
HIV prevalence. Now, Uganda is once again in the 
global spotlight, but as an example of one of the first 
countries in which clinics are routinely turning people 
away from care.3  
In order to better understand the medical and 
public health principles of HIV/AIDS care and how 
treatment decisions are being made in resource-poor 
settings, I traveled to Uganda recently to complete a 
month-long medical student clinical elective.  I visited 
Makerere University’s Infectious Disease Institute 
(IDI) in Kampala, one of the country’s state-of-the-art 
HIV research and treatment facilities. This was my 
ninth trip to Uganda; the first was during the mid-
1990s, when HIV prevalence was around 15% and 
coffin shops lined the roads out of the capital city. 
Today, the HIV prevalence in Uganda is 5.7% and 
Kampala has the chaotic, palpable energy inherent 
in all cities undergoing tremendous development 
and growth.4 According to 2009 data, the number of 
Ugandans living with HIV in was 1 million, with only 
11% receiving anti-retroviral treatment.5,6 
A non-governmental organization (NGO), the IDI 
was established in 2004.  It  focuses on strengthening 
the care and treatment of HIV and related infectious 
diseases for people living with HIV across Africa 
by offering professional training for health workers, 
conducting research on best practices related to 
HIV in low resource settings, and advancing clinical 
services that support the development of new models 
of HIV/AIDS care. The IDI started at a time when 
ART was becoming more widely available in countries 
where there were not enough clinicians to implement 
treatment programs.7 
Approximately 9,000 people currently receive care 
at the IDI clinic, and an additional 6,000 receive care 
through outreach activities.7  These patients, who 
often travel from great distances, wait for hours with 
hundreds of other patients, many of them quite 
sick, to be monitored during routine visits. Due to 
sheer volume, physicians and providers at the IDI 
see an average of 60 patients per day.  Many patients 
that receive care at IDI do not qualify for treatment 
with ART based on their T-cell count. According to 
the World Health Organization’s clinical guidelines, 
patients with T-cell counts below 350 should receive 
ART.8 However, in Uganda, like most resource-poor 
countries that cannot afford to treat patients based 
on this guideline, the T-cell count cut off is 250 for 
initiation of ART.  Financial circumstances are forcing 
physicians to apply sub-optimal criteria of care for 
patients, including denying medications to those who 
actually do clinically qualify for treatment. During my 
rotation, I watched clinicians turn away patients and 
make the sometimes impossible decisions regarding 
who should be treated and why. Importantly, these 
funding shortages also force patients to watch loved 
ones suffer and make the difficult decision to share 
or sell medications, which can ultimately lead to 
treatment resistance. 
Although my clinical rotation at the IDI was, in part, 
about learning how to provide appropriate medical 
care to persons with HIV/AIDS in Uganda, it was 
also about re-examining a country that I care deeply 
about at this specific point in history. As always, I 
am inspired and impressed by Uganda’s dedication 
to extraordinary research in the field of HIV/AIDS. 
It is a country that, through research and example, 
continues to provide the scientific foundation for 
HIV treatment in resource-poor settings. At the 
same time, I am angry and deeply saddened that the 
current level of global commitment to HIV/AIDS 
prevents clinicians from successfully translating this 
research into a model of clinical care that minimizes 
suffering and emphasizes principles of health equity.  
When I read about the Global Fund’s fundraising 
failure, the faces of the many HIV-positive patients I 
saw in Uganda flashed through my mind.  What will 
happen to them? The difficult reality is that, almost 
thirty years into the global HIV/AIDS pandemic, 
most of these patients with HIV, and those who will 
become infected, will die without ever accessing life-
saving treatment.  
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